Over the past few months we have chronicled the many issues facing Tandem (NASDAQ: TNDM). What seemed somewhat odd was how the company has reacted to these issues. From all outward appearances, the situation was not just bleak but getting rather desperate. Year to date shares have fallen 68%, the company is running out of cash and has more than $80 million in debt. As of yesterday, they had a market cap of just under $35 million.
To make matters worse Tandem plays in a highly competitive sandbox. Even with Medtronic’s (NYSE: MDT) recent issues with the . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.